Science Explorer Back to mapMap

Most cited papers from Neuronetics (United States)

What are the most cited papers from Neuronetics (United States)?

The most cited paper from Neuronetics (United States) is "Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial" (John P. O’Reardon, H. Brent Solvason, Philip G. Janicak et al., 2007), with 1,941 citations. Next come "TRANSCRANIAL MAGNETIC STIMULATION (TMS) FOR MAJOR DEPRESSION: A MULTISITE, NATURALISTIC, OBSERVATIONAL STUDY OF ACUTE TREATMENT OUTCOMES IN CLINICAL PRACTICE" (372) and "Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial" (285).

Showing 50 of 87 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial John P. O’Reardon, H. Brent Solvason, Philip G. Janicak et al. · Biological Psychiatry 31 Jul 2007 1,941
2 TRANSCRANIAL MAGNETIC STIMULATION (TMS) FOR MAJOR DEPRESSION: A MULTISITE, NATURALISTIC, OBSERVATIONAL STUDY OF ACUTE TREATMENT OUTCOMES IN CLINICAL PRACTICE Linda L. Carpenter, Philip G. Janicak, Scott T. Aaronson et al. · Depression and Anxiety 11 Jun 2012 372
3 Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial Michael J. Detke, Curtis G. Wiltse, Craig H. Mallinckrodt et al. · European Neuropsychopharmacology 16 Mar 2004 285
4 The Risk of Switch to Mania in Patients With Bipolar Disorder During Treatment With an Antidepressant Alone and in Combination With a Mood Stabilizer Alexander Viktorin, Paul Lichtenstein, Michael E. Thase et al. · American Journal of Psychiatry Open access 17 Jun 2014 250
5 Transcranial Magnetic Stimulation in the Treatment of Major Depressive Disorder Philip G. Janicak, John P. O’Reardon, Shirlene M. Sampson et al. · The Journal of Clinical Psychiatry 15 Feb 2008 237
6 Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome Leslie J. Crofford, Elizabeth A. Young, N. Cary Engleberg et al. · Brain Behavior and Immunity 27 Feb 2004 233
7 Clinical outcomes in a large registry of patients with major depressive disorder treated with Transcranial Magnetic Stimulation Harold A. Sackeïm, Scott T. Aaronson, Linda L. Carpenter et al. · Journal of Affective Disorders Open access 7 Aug 2020 202
8 Low-Dose Recombinant Tissue-Type Plasminogen Activator Enhances Clot Resolution in Brain Hemorrhage Neal J. Naff, Michael Allen Williams, Penelope M. Keyl et al. · Stroke Open access 25 Aug 2011 176
9 Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study Philip G. Janicak, Ziad H. Nahas, Sarah Hollingsworth Lisanby et al. · Brain stimulation Open access 12 Aug 2010 170
10 The bouba/kiki effect is robust across cultures and writing systems Aleksandra Ćwiek et al. · Philosophical Transactions of the Royal Society B Biological Sciences Open access 15 Nov 2021 169
11 Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial Paul E. Croarkin, Ahmed Z. Elmaadawi, Scott T. Aaronson et al. · Neuropsychopharmacology Open access 12 Sep 2020 134
12 Transcranial Magnetic Stimulation in the Acute Treatment of Major Depressive Disorder David Avery, K E Isenberg, Shirlene M. Sampson et al. · The Journal of Clinical Psychiatry 15 Mar 2008 131
13 Transcranial magnetic stimulation in autism spectrum disorder: Challenges, promise, and roadmap for future research Lindsay M. Oberman, Peter G. Enticott, Manuel Fernando Casanova et al. · Autism Research Open access 4 Nov 2015 114
14 Curcuma longa Extract Protects against Gastric Ulcers by Blocking H2 Histamine Receptors Dong Chan Kim, Sun-Hee Kim, Bo-Hwa Choi et al. · Biological and Pharmaceutical Bulletin Open access 2005 98
15 Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis Kit N. Simpson, Mary Jane Welch, Frank Andrew Kozel et al. · Advances in Therapy Mar 2009 96
16 Human adult bone marrow-derived somatic cells rescue vision in a rodent model of retinal degeneration Bin Lü, S. Wang, Sergey Girman et al. · Experimental Eye Research 6 Jul 2010 95
17 The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression Jared Cooney Horvath, John Mathews, Mark A. Demitrack et al. · Journal of Visualized Experiments Open access 12 Nov 2010 83
18 Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite Randomized Pilot Study Noah S. Philip, David L. Dünner, Sheila M. Dowd et al. · Brain stimulation Open access 25 Nov 2015 80
19 Comparison of clinical outcomes with two Transcranial Magnetic Stimulation treatment protocols for major depressive disorder LindaL. Carpenter, ScottT. Aaronson, Todd M. Hutton et al. · Brain stimulation Open access 18 Dec 2020 60
20 Suppressing the Surface Field During Transcranial Magnetic Stimulation KENT R. DAVEY, Mark Riehl · IEEE Transactions on Biomedical Engineering 25 Jan 2006 60
21 Comparison of clinical outcomes with left unilateral and sequential bilateral Transcranial Magnetic Stimulation (TMS) treatment of major depressive disorder in a large patient registry Scott T. Aaronson, Linda L. Carpenter, Todd M. Hutton et al. · Brain stimulation Open access 22 Jan 2022 51
22 Improvement in Quality of Life With Left Prefrontal Transcranial Magnetic Stimulation in Patients With Pharmacoresistant Major Depression: Acute and Six Month Outcomes H. Brent Solvason, Mustafa M. Husain, Paul Bernard Fitzgerald et al. · Brain stimulation Open access 4 Nov 2013 48
23 Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice Philip G. Janicak, David L. Dünner, Scott T. Aaronson et al. · CNS Spectrums Open access 30 Jul 2013 44
24 Clinical Significance of Transcranial Magnetic Stimulation (TMS) in the Treatment of Pharmacoresistant Depression: Synthesis of Recent Data Mark A. Demitrack, Michael E. Thase · Psychopharmacology Bulletin 12 Aug 2025 43
25 Designing transcranial magnetic stimulation systems KENT R. DAVEY, Mark Riehl · IEEE Transactions on Magnetics Mar 2005 40
26 Left dorsolateral prefrontal transcranial magnetic stimulation (TMS): Sleep factor changes during treatment in patients with pharmacoresistant major depressive disorder Peter B. Rosenquist, Andrew D. Krystal, Karen L. Heart et al. · Psychiatry Research 26 Sep 2012 38
27 A Double-blind, Placebo-Controlled Study of the Impact of Galantamine on Anterograde Memory Impairment During Electroconvulsive Therapy John Matthews, Caleb J. Siefert, Mark A. Blais et al. · Journal of Ect 22 Mar 2013 34
28 Linking disease symptoms and subtypes with personalized systems-based phenotypes: A proof of concept study Kirstin Aschbacher, Emma Kristine Adam, Leslie J. Crofford et al. · Brain Behavior and Immunity Open access 9 Jun 2012 33
29 Treatment-Resistant Depression in Adolescents: Clinical Features and Measurement of Treatment Resistance Jeffrey Robert Strawn, Scott T. Aaronson, Ahmed Z. Elmaadawi et al. · Journal of Child and Adolescent Psychopharmacology Open access 21 Apr 2020 20
30 Effectiveness of NeuroStar transcranial magnetic stimulation (TMS) in patients with major depressive disorder with postpartum onset David G. Brock, Mark A. Demitrack, Pashia Groom et al. · Brain stimulation Open access 27 Aug 2016 20
31 Neurosensory Symptom Complexes after Acute Mild Traumatic Brain Injury Michael E. Hoffer, Mikhaylo Szczupak, Alexander Kiderman et al. · PLoS ONE Open access 4 Jan 2016 20
32 Treatment-Resistant Depression Philip G. Janicak, Sheila M. Dowd · Psychopharm Review Jun 2009 17
33 Preparation and characterization of stable phospholipid–silica nanostructures loaded with quantum dots Natalia V. Beloglazova, Irina Yu. Goryacheva, ПАВЕЛ СЕРГЕЕВИЧ ШМЕЛИН et al. · Journal of Materials Chemistry B 21 Nov 2014 16
34 The dynamics of indexical information in speech: Can recognizability be controlled by the speaker? Volker Dellwo, Elisa Pellegrino, Lei He et al. · AUC PHILOLOGICA Open access 18 Oct 2019 7
35 The Use and Clinical Significance of Transcranial Magnetic Stimulation in the Treatment of Major Depression Mark A. Demitrack · Psychopharm Review Jun 2007 7
36 Clinical methodology and its implications for the study of therapeutic interventions for chronic fatigue syndrome: a commentary Mark A. Demitrack · Pharmacogenomics Apr 2006 5
37 A Multisite, 6-Month, Open-Label Study of Maintenance Transcranial Magnetic Stimulation for Adolescents with Treatment-Resistant Depression Juan Felipe Garzon, Ahmed Z. Elmaadawi, Scott T. Aaronson et al. · Journal of Child and Adolescent Psychopharmacology Open access 24 Dec 2024 4
38 Transcranial Magnetic Stimulation for the Treatment of Major Depression Mark A. Demitrack · Psychopharm Review Apr 2010 4
39 Characterization of a Novel Human Anti-HIV-1 gp41 IgM Monoclonal Antibody Designated Clone 37 Chuanhai Cao, Yun Bai, Mary Jolene Holloway et al. · DNA and Cell Biology Dec 2004 4
40 160 Optimizing TMS Treatment for Depression - The 19 Minute Dash™ Protocol Miriam Mina, David G. Brock, Álvaro Pascual‐Leone et al. · CNS Spectrums Open access Feb 2018 3
41 Asenapine Philip G. Janicak, Jeffrey T. Rado · Psychopharm Review Dec 2009 3
42 Post Marketing Rate of Seizures During Transcranial Magnetic Stimulation (TMS) Treatment with NeuroStar Advanced Therapy Is Lower Than Previously Estimated Bridget A. McGugan, Karen L. Heart, David G. Brock et al. · Brain stimulation Open access Nov 2020 2
43 166 Post Market Rate of Seizures During TMS Treatment with NeuroStar® System Appears to Be Lower than Previously Estimated Paul Janicak, Karen L. Heart, Bridget A. McGugan · CNS Spectrums Open access Apr 2020 2
44 Development of a Magneto-Rheological Fluid-Based Trim Actuator with Active Tactile Cueing Capabilities Guifré Julió, Geoffrey Latham, Jean‐Sébastien Plante Conference paper 5 May 2015 2
45 Clinical Perspectives on Antidepressant Drug Development: A Critical Discussion Mark A. Demitrack · Current Pharmaceutical Design 2005 2
46 Age is just a number: real-world effectiveness of TMS in late-life depression Eleanor J. Cole, Scott T. Aaronson, Linda L. Carpenter et al. · Brain stimulation Open access 2025 1
47 Treating Schizophrenia and Bipolar I Disorder in the Real-World Setting Maxwell Zachary Price, Richard Louis Price · The Primary Care Companion For CNS Disorders Open access 2 Apr 2024 1
48 Reduction of Pain-Related Symptoms with Transcranial Magnetic Stimulation (TMS) Treatment in Depressed Patients Mark A. Demitrack, David G. Brock · Brain stimulation 28 Jan 2015 1
49 A Contribution to the Role of the Claustrum in Speech Motor Control Processes Manfred Pützer, Jean Richard Moringlane, W. Reith et al. · SSRN Electronic Journal PreprintOpen access 2021 1
50 the Alignment Paradigm for Modeling the Self Alexandre Pitti · HAL (Le Centre pour la Communication Scientifique Directe) Conference paperOpen access 2017 1

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.